Bortezomib for Refractory Antibody-mediated Cardiac Allograft Rejection.

Eckman PM, Thorsgard M, Maurer D, Kim Y, Alloway RR, Woodle ES.

Clinical Transplants 2009, Chapter 50

Abstract

This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.